Maxim Group Reinstates Buy on Filana Therapeutics, Announces $5 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Maxim Group analyst Jason McCarthy reinstates Filana Therapeutics (NASDAQ:FLNA) with a Buy and announces $5 price target.
Maxim Group analyst Jason McCarthy reinstates Filana Therapeutics (NASDAQ:FLNA) with a Buy and announces $5 price target.